This move comes amid growing opportunities for the company’s wearable ultrasound technology in the North American healthcare, wellbeing and fitness monitoring markets.

Mr Jolliffe previously served as finance director of UK Power Operations at Scottish Power, chief executive of Pyroguard, a subsidiary of CGI International, and most recently the CFO at Optoscribe – a tech firm specialising in developing 3D lasers for telecommunications which was acquired by Intel in 2022.

Dave Hughes, CEO and co-founder of Novosound, stated: “It’s a remarkable coup to have David, a seasoned executive with a wealth of international experience from thriving technology companies and global industrial giants, join our team.

“Over the past year, we’ve experienced a transformative journey, doubling our revenues consecutively.

“As we embark on the next phase of growth and secure contracts across the UK, Europe, and North America, having David on board in Scotland, the birthplace of ultrasound, is invaluable. His guidance will shape our strategy and operations for continued success.”

Under the stewardship of Mr Jolliffe, Novosound aims to leverage its commercially available ultrasound technology, capitalising on the latest advancements, such as the ultrasound system-on-patch (USoP) tech and the Internet of Medical Things (IoMT).

The company recently launched a new leadership team, including Simon Patterson as chief commercial officer, and Gwen Grant as chief administrative officer, alongside Mr Hughes and Mr Jolliffe.

In December, Novosound signed a commercial partnership with Nasdaq-listed medical tech firm PAVmed Inc., further establishing its presence in the healthcare sector and advancing its expansion in North America. The company’s track record includes contracts with BAE Systems, GE Aviation, and Israeli digital health firm dSound.

Novosound’s growth trajectory has been fuelled by its latest £3.7 million investment round in 2022, led by Par Equity and supported by Foresight Group, Kelvin Capital, and Scottish Enterprise.